About this Research Topic
Acute lymphoblastic leukemia (ALL) is a hematological malignancy derived from B- or T- lymphoid progenitors that show high heterogeneity, affecting 25% of children and young adults worldwide. A series of genetic and epigenetic alterations had been linked to this disease, including N/Fmut, PTEN, JAK2, RAS, and KMT2A mutations, among others. Recently, non-coding RNAs (ncRNAs) also have been used as prognostic signatures, and novel treatments are being proposed based on lncRNAs, circRNAs, microRNAs, chimeric antigen receptor (CAR) T-cell, stem cell, and targeted regulation of the epigenetic mechanisms. Prognostic monograms have been shown to have a significant impact in predicting both event-free survival and overall survival of patients with ALL high-risk signatures that are more likely to have poor outcomes and cancer relapse. These studies are based on expression profiling and genomic signatures that identify patterns of molecular markers that can help predict the likelihood of disease progression, recurrence, and response to therapy. Therefore, accurate prognosis of new ALL treatments is crucial to promote more effective clinical practice and personalized treatment decisions.
In this Research Topic, we aim to promote discussion on emerging research of novel targeted strategies for treating children and young adults with ALL with significant prognostic impact on monitoring of disease progression and therapy outcomes. We welcome submissions on prognostic monograms of new therapies for pediatric ALL that cover but are not limited to:
- Chimeric antigen receptor (CAR) T-cell therapy
- Stem cell therapy
- Genetic and epigenetic predictors and therapeutics
- ncRNAs as prognostic biomarkers and therapeutics
Please note: manuscripts consisting solely of bioinformatics or computational analysis of public genomic or transcriptomic databases which are not accompanied by validation (independent cohort or biological validation in vitro or in vivo) are out of scope for this section and will not be accepted as part of this Research Topic.
In this Research Topic, we aim to promote discussion on emerging research of novel targeted strategies for treating children and young adults with ALL with significant prognostic impact on monitoring of disease progression and therapy outcomes. We welcome submissions on prognostic monograms of new therapies for pediatric ALL that cover but are not limited to:
- Chimeric antigen receptor (CAR) T-cell therapy
- Stem cell therapy
- Genetic and epigenetic predictors and therapeutics
- ncRNAs as prognostic biomarkers and therapeutics
Please note: manuscripts consisting solely of bioinformatics or computational analysis of public genomic or transcriptomic databases which are not accompanied by validation (independent cohort or biological validation in vitro or in vivo) are out of scope for this section and will not be accepted as part of this Research Topic.
Keywords: prognostic monograms, ALL therapy, gene mutation, epigenetic, stem cell therapy, CAR-T-cell immunotherapy
Important Note: All contributions to this Research Topic must be within the scope of the section and journal to which they are submitted, as defined in their mission statements. Frontiers reserves the right to guide an out-of-scope manuscript to a more suitable section or journal at any stage of peer review.
